March 18 (Reuters) - Sarepta Therapeutics Inc :
* SAREPTA THERAPEUTICS’ INVESTIGATIONAL GENE THERAPY SRP-9003 FOR THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2E SHOWS SUSTAINED EXPRESSION AND FUNCTIONAL IMPROVEMENTS 2 YEARS AFTER ADMINISTRATION
* SAREPTA THERAPEUTICS INC - RESULTS IN BOTH COHORTS CONTINUE TO REINFORCE SAFETY AND TOLERABILITY PROFILE OF SRP-9003
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* SAREPTA THERAPEUTICS’ INVESTIGATIONAL GENE THERAPY SRP-9003 FOR THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2E SHOWS SUSTAINED EXPRESSION AND FUNCTIONAL IMPROVEMENTS 2 YEARS AFTER ADMINISTRATION
* SAREPTA THERAPEUTICS INC - RESULTS IN BOTH COHORTS CONTINUE TO REINFORCE SAFETY AND TOLERABILITY PROFILE OF SRP-9003
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)